https://pipelinereview.com/Oxurion-Enrolls-First-Patient-in-Phase-2-Clinical-Study-Evaluating-THR-317-anti-PlGF-for-treatment-of-Idiopathic-Macular-Telangiectasia-Type-1-MacTel-1/